Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif
- PMID: 16337683
- DOI: 10.1016/j.molimm.2005.10.009
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif
Abstract
Tumor homing peptides containing the NGR motif, such as CNGRC and GNGRG, have been used for delivering cytokines, chemotherapeutic drugs, apoptotic peptides, and liposomes to a CD13 isoform expressed in tumor blood vessels. In view of the potential clinical applications of these drugs and considering the risk that NGR peptides could elicit blocking antibodies we have investigated the immunogenic properties of CNGRC and GNGRG in mice and rabbits, using various products containing these residues and different administration schedules. The results suggest that the immunogenicity of the NGR motif is very low, even when it is conjugated to tumor necrosis factor-alpha or to highly immunogenic carrier proteins. Molecular dynamics simulation experiments showed that both peptides have a strong propensity to populate a turn conformation. Superposition of predicted structures to the CTGNGRGEWKC loop of the 5th type I repeat of human fibronectin, a protein that contains four NGR motives, showed that the root mean square deviation of backbones was 0.7A for GNGRG and 0.5A for NGR. These results suggest that NGR peptides could mimic from an immunological point of view a "self" structure, likely the GNGRG loop of fibronectin, with important implications for the use of these targeting peptides in patients.
Similar articles
-
Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.J Biol Chem. 2010 Mar 19;285(12):9114-23. doi: 10.1074/jbc.M109.044297. Epub 2010 Jan 11. J Biol Chem. 2010. PMID: 20064928 Free PMC article.
-
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.Cancer Res. 2002 Feb 1;62(3):867-74. Cancer Res. 2002. PMID: 11830545
-
Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif.J Biol Chem. 2002 Dec 6;277(49):47891-7. doi: 10.1074/jbc.M207500200. Epub 2002 Oct 7. J Biol Chem. 2002. PMID: 12372830
-
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.Ann N Y Acad Sci. 2004 Dec;1028:104-12. doi: 10.1196/annals.1322.011. Ann N Y Acad Sci. 2004. PMID: 15650236 Review.
-
The neovasculature homing motif NGR: more than meets the eye.Blood. 2008 Oct 1;112(7):2628-35. doi: 10.1182/blood-2008-04-150862. Epub 2008 Jun 23. Blood. 2008. PMID: 18574027 Free PMC article. Review.
Cited by
-
Succinimide Formation from an NGR-Containing Cyclic Peptide: Computational Evidence for Catalytic Roles of Phosphate Buffer and the Arginine Side Chain.Int J Mol Sci. 2017 Feb 16;18(2):429. doi: 10.3390/ijms18020429. Int J Mol Sci. 2017. PMID: 28212316 Free PMC article.
-
A unified mechanism for aminopeptidase N-based tumor cell motility and tumor-homing therapy.J Biol Chem. 2014 Dec 12;289(50):34520-9. doi: 10.1074/jbc.M114.566802. Epub 2014 Oct 29. J Biol Chem. 2014. PMID: 25359769 Free PMC article.
-
Structure and activity of CPNGRC: a modified CD13/APN peptidic homing motif.Chem Biol Drug Des. 2010 Jun;75(6):551-62. doi: 10.1111/j.1747-0285.2010.00974.x. Epub 2010 Mar 30. Chem Biol Drug Des. 2010. PMID: 20374250 Free PMC article.
-
iso-DGR sequences do not mediate binding of fibronectin N-terminal modules to adherent fibronectin-null fibroblasts.J Biol Chem. 2010 Mar 19;285(12):8563-71. doi: 10.1074/jbc.M109.062646. Epub 2010 Jan 22. J Biol Chem. 2010. PMID: 20097751 Free PMC article.
-
Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.J Biol Chem. 2010 Mar 19;285(12):9114-23. doi: 10.1074/jbc.M109.044297. Epub 2010 Jan 11. J Biol Chem. 2010. PMID: 20064928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous